Diazepam is a benzodiazepine medication that is FDA approved for the management of anxiety disorders, short-term relief of anxiety symptoms, spasticity associated with upper motor neuron disorders, adjunct therapy for muscle spasms, preoperative anxiety relief, management of certain refractory epilepsy patients, and adjunct in severe recurrent convulsive seizures, and an adjunct in status epilepticus. Off-label (non-FDA approved) use for diazepam includes sedation in the ICU and short-term treatment of spasticity in children with cerebral palsy. This activity will highlight the mechanism of action, adverse event profile, approved and off-label uses, dosing, pharmacodynamics, pharmacokinetics, monitoring, and relevant interactions of diazepam, pertinent for interprofessional team members using diazepam for any of its intended indications.
Identify the indications for using diazepam.
Summarize the adverse effects, contraindications of diazepam.
Review the mechanism of action of diazepam.
Outline the importance of improving care coordination among the interprofessional team to enhance the delivery of care for patients when using diazepam.
Diazepam is an anxiolytic benzodiazepine, first patented and marketed in the United States in 1963. It is a fast-acting, long-lasting benzodiazepine commonly used to treat anxiety disorders and alcohol detoxification, acute recurrent seizures, severe muscle spasms, and spasticity associated with neurologic disorders. In the setting of acute alcohol withdrawal, diazepam is useful for symptomatic relief of agitation, tremor, alcoholic hallucinosis, and acute delirium tremens. Benzodiazepines have largely replaced barbiturates in treating anxiety and sleep disorders because of their improved safety profile, fewer side effects, and flumazenil(antagonist) availability that can reverse oversedation in cases of benzodiazepine intoxication.
Diazepam is FDA approved for the management of anxiety disorders, short-term relief of anxiety symptoms, spasticity associated with upper motor neuron disorders, adjunct therapy for muscle spasms, preoperative anxiety relief, management of certain refractory epilepsy patients and adjunct in severe recurrent convulsive seizures, and an adjunct in status epilepticus. Off-label (non-FDA approved) use for diazepam includes sedation in the ICU and short-term treatment of spasticity in children with cerebral palsy.
Mechanism of Action
Benzodiazepines exert their effects by facilitating the activity of gamma-aminobutyric acid(GABA) at various sites. Specifically, benzodiazepines bind at an allosteric site at the interface between the alpha and gamma subunits on GABA-A receptor chloride ion channels. The allosteric binding of diazepam at the GABA-A receptor leads to an increase in the frequency at which the chloride channel opens, leading to an increased conductance of chloride ions. This shift in charge leads to a hyperpolarization of the neuronal membrane and reduced excitability of the neuron.
Specifically, the allosteric binding within the limbic system leads to the anxiolytic effects seen with diazepam. Allosteric binding within the spinal cord and motor neurons is the primary mediator of the myorelaxant effects seen with diazepam. Mediation of the sedative, amnestic, and anticonvulsant effects of diazepam is through receptor binding within the cortex, thalamus, and cerebellum.
Diazepam is highly lipophilic. While there is a moderately quick onset of action, the drug quickly redistributes. Diazepam is mostly broken down by the microsomal enzymes CYP2C19 and CYP3A4 enzymes to several active metabolites, mainly desmethyldiazepam. Other minor active metabolites include oxazepam and temazepam. The average half-lives of oral diazepam and desmethyldiazepam are about 46 hours and 100 hours, respectively.
Potent inhibition of the CYP2C19 enzyme by certain drugs (fluoxetine and chloramphenicol) and CYP3A4 enzymes by certain medications (ketoconazole, protease inhibitors, erythromycin) may cause increased levels of diazepam. In contrast, inducers of CYP2C19 (rifampicin and prednisone) and CYP3A4 (carbamazepine, topiramate, phenytoin, St. John's wort, rifampin, or barbiturates) may cause lower levels. Metabolites of diazepam are conjugated with glucuronide and excreted almost entirely in the urine.
Diazepam is available in multiple formulations, including oral tablets, intramuscular injections (IM), intravenous injection (IV), or rectal gel. Oral tablets have a more reliable absorption and controlled release when compared to IM. When administered intravenously, diazepam has an onset of action within 1 to 3 minutes, while oral dosing onset ranges between 15 to 60 minutes. Diazepam is long-lasting with a duration of action of more than 12 hours.
Treatment of acute ethanol withdrawal: Initial dosing should be 10 mg IM or IV. If needed, a follow-up dose of 5 to 10 mg is permissible 3 to 4 hours later. If using the oral tablet, dosing is 10 mg every 6 to 8 hours within the first 24 hours, then 5mg every 6 to 8 hours thereafter as needed.
Treatment of anxiety: 2 to 10 mg can be given orally 2 to 4 times daily. If given parentally, dosing can be 2 to 10 mg and repeated in 3 to 4 hours, if needed.
Treatment of muscle spasm: 2 to 10 mg can be given orally 3 to 4 times daily. If given parentally, an initial dose of 5 to 10 mg can be followed by another 5-10mg dose in 3 to 4 hours, if necessary.
Treatment of preoperative anxiety: Dosing is 10 mg IM before surgery.
For sedation in the ICU: Loading dose of 5 to 10 mg for initial administration, followed by a maintenance dose of 0.03 to 0.10 mg/kg every 0.5 to 6 hours. (Barr 2013)
Treatment of seizures: 2 to 10 mg orally dosed 2 to 4 times daily as adjunctive maintenance therapy. For intermittent management of seizures, rectal gel 0.2mg/kg is an option. It may be repeated in 4 to 12 hours if needed. Do not exceed five uses per month or more than one dose every five days.
Skeletal muscle relaxant: 2 to 10 mg, dosed 3 to 4 times daily as an adjunct therapy.
Treatment of status epilepticus: 0.15 to 0.20 mg/kg IV per dose and may be repeated once needed. Do not exceed 10 mg per single dose. Rectal administration of 0.2 to 0.5 mg/kg administered one time. Do not exceed 20 mg per dose.
Like most benzodiazepines, the adverse reactions of diazepam include CNS and respiratory depression, dependence, and benzodiazepine withdrawal syndrome.
Contraindications to diazepam include patients with a known hypersensitivity to diazepam. Diazepam is also contraindicated in patients under 6 months of age. Other contraindications to diazepam include patients with severe respiratory insufficiency, myasthenia gravis, sleep apnea syndrome, and severe hepatic insufficiency. It is permissible in patients with open-angle glaucoma receiving appropriate therapy but is contraindicated in acute narrow-angle glaucoma.
Use in Special Populations
Diazepam classifies as FDA pregnancy category D, which means that there is positive evidence of human fetal risk. Still, the benefits from use in pregnant women may be acceptable despite the risk. The use of diazepam and other benzodiazepines in pregnancy correlates with an increased risk of congenital malformations, premature birth, low birth weight, and other neurodevelopmental abnormalities. However, additional studies are needed to confirm.
Diazepam readily crosses the placental barrier, and use during pregnancy may result in neonatal withdrawal soon after birth. Symptoms of neonatal withdrawal include high-pitched cry, hypertonia, tremor, irritability, feeding difficulties, sleep/wake disturbances, gastrointestinal and autonomic disturbances, respiratory problems, and failure to thrive. The onset of withdrawal in a neonate whose mother has taken diazepam during the pregnancy could be anywhere from the first days of life to the first few weeks. During the last trimester of pregnancy, diazepam use can result in “floppy infant syndrome,” characterized by hypotonia, hypothermia, lethargy, respiratory distress, and suckling difficulties.
Diazepam and its metabolites are excreted in breast milk and may produce effects in the nursing infant. Some studies have shown the relative infant dose (RID) of diazepam to be approximately 9%. Relative infant dose (RID) is the dose received via breast milk relative to the mother’s dose. A relative dose below 10% is within an acceptable range regarded as reasonably safe in the short term. However, due to diazepam’s long half-life, metabolites may accumulate in a breastfed infant. Therefore, the clinician should monitor an infant breastfed by a mother receiving diazepam for drowsiness, decreased feeding, lethargy, and failure to thrive. Discontinue breastfeeding in cases with high doses of diazepam or when repeated administration will be necessary.
One should exercise caution when prescribing diazepam to the older population. Elderly patients tend to have decreased renal function and clearing capability; therefore, this population is at an increased risk of diazepam accumulation and its major metabolites. The recommendation is to limit the dosage to the smallest effective amount. Paradoxical reactions of CNS hyperactivity have also been reported when using benzodiazepines in the elderly, manifesting as hyperactivity, aggressive behavior, irritability, anxiety, and hallucinations. Should this occur, discontinuation is the recommendation.
US Boxed Warning
Simultaneous use of benzodiazepines and opioids may result in respiratory depression, profound sedation, coma, and death. Reserve concomitant prescribing of these drugs for patients for whom alternative treatment options are inadequate. Minimize dose to the minimum to prevent fatal respiratory depression.
It is crucial to monitor respiratory and cardiovascular status, blood pressure, heart rate, and anxiety symptoms in patients taking diazepam. With long-term use, monitor liver enzymes, CBC, and for signs of propylene glycol toxicity, including serum creatinine, BUN, serum lactate, and osmolality gap. With critically ill patients, monitor the depth of sedation.
The toxic-to-therapeutic ratio of benzodiazepines is very high, making them relatively safe medications. However, the potential of overdose from diverted diazepam always exists when combined with opioids, alcohol, or other centrally acting agents. Overdose in adults frequently involves the co-ingestion of other CNS depressants, which work synergistically to increase toxicity. In the case of single-agent diazepam overdose, symptoms manifest as CNS depression and are very rarely fatal. In mild cases, lethargy, drowsiness, and confusion are common symptoms. In cases of severe overdose, symptoms manifest as ataxia, diminished reflexes, hypotonia, hypotension, respiratory depression, coma (rarely), and death (very rarely).
Treatment of benzodiazepine overdose involves protecting the airway, fluid resuscitation, and the use of flumazenil if indicated. Flumazenil works via competitive antagonism at the benzodiazepine receptor and can rapidly reverse coma. However, in patients with benzodiazepine tolerance, the use of flumazenil can precipitate acute withdrawal symptoms, autonomic instability, and seizures.
Potential for Diazepam Abuse and Dependence
Diazepam is a Schedule IV controlled substance with the potential for abuse. Development of dependence and tolerance can occur in addiction-prone, long-term treatment or those patients taking high doses. Thus, these individuals should be under careful supervision. Once an individual develops dependence, the risk of developing withdrawal symptoms increases. Signs of benzodiazepine withdrawal include tremor, rebound anxiety, perceptual disturbances, dysphoria, psychosis, agitation, irritability, restlessness, sweating, headache, confusion, myalgias, abdominal pain, and vomiting. In long-term use and abrupt cessation, there is potential for hallucinations and epileptic seizures to occur.
Propylene Glycol Toxicity
Propylene glycol toxicity is a rare toxidrome associated with the parenteral use of diazepam. Propylene glycol is a common diluent used in the suspension of IV diazepam. Large doses or long-term infusions of IV diazepam can cause accumulation of propylene glycol and subsequent anion gap metabolic acidosis. Signs of propylene glycol poisoning include the development of serum hyperosmolality, hemolysis, cardiac dysrhythmias, hypotension, lactic acidosis, seizure, acute kidney injury, and multisystem organ failure.
Enhancing Healthcare Team Outcomes
Diazepam is a fast-acting potent anxiolytic popular due to its broad therapeutic index, low toxicity, and improved safety profile. Nonetheless, diazepam is still a drug with high potential for use disorder associated with severe adverse/toxic effects. Therefore, clinicians should identify the proper indication for the prescription of diazepam. Psychiatrist consultation is necessary in the cases of anxiety disorders. Neurologists should prescribe diazepam in spasticity and status epilepticus, considering the risk vs. benefit ratio for the individual patients. The pharmacists are responsible for proper dosing of diazepam and medication reconciliation. The pharmacist should report back to the clinician if there are significant interactions.
In acute overdose of diazepam, triage nurses and emergency department physicians are responsible for rapid diagnosis and stabilization of the patient. Critical care physicians should manage respiratory depression and which can be life-threatening if not treated promptly. In ICU, regular assessment of RASS(Richmond agitation-sedation scale) and CAM-ICU(confusion assessment method for the ICU) scoring should guide the proper use of sedatives. Consulting the psychiatrist is especially important if the diazepam overdose is intentional.
As illustrated above, managing patients on diazepam requires an interprofessional team approach consisting of clinicians(MDs, DOs, NPs, PAs), specialists, nurses, pharmacists, and other healthcare providers. Further, prescribing physicians should be responsible for checking state and federal controlled substance databases to detect benzodiazepines use disorder, diversion, and prevent improper drug use. An interprofessional team approach would achieve maximum efficacy and minimize potential adverse drug reactions for the patients requiring diazepam, which can translate to better patient outcomes. [level 5]
(Click Image to Enlarge)
Chemical Structure of Diazepam
Contributed by US National Library of Medicine
Nutt DJ,Malizia AL, New insights into the role of the GABA(A)-benzodiazepine receptor in psychiatric disorder. The British journal of psychiatry : the journal of mental science. 2001 Nov; [PubMed PMID: 11689393]
Pekcan M,Celebioglu B,Demir B,Saricaoglu F,Hascelik G,Yukselen MA,Basgul E,Aypar U, The effect of premedication on preoperative anxiety. Middle East journal of anaesthesiology. 2005 Jun [PubMed PMID: 16438017]
Seldenrijk A,Vis R,Henstra M,Ho Pian K,van Grootheest D,Salomons T,Overmeire F,de Boer M,Scheers T,Doornebal-Bakker R,Ruhé HG,Vinkers CH, [Systematic review of the side effects of benzodiazepines]. Nederlands tijdschrift voor geneeskunde. 2017 [PubMed PMID: 29076441]
Park MY,Kim WJ,Lee E,Kim C,Son SJ,Yoon JS,Kim W,Namkoong K, Association between use of benzodiazepines and occurrence of acute angle-closure glaucoma in the elderly: A population-based study. Journal of psychosomatic research. 2019 Jul; [PubMed PMID: 31126405]
Bellantuono C,Tofani S,Di Sciascio G,Santone G, Benzodiazepine exposure in pregnancy and risk of major malformations: a critical overview. General hospital psychiatry. 2013 Jan-Feb; [PubMed PMID: 23044244]
Dallmann A,Ince I,Coboeken K,Eissing T,Hempel G, A Physiologically Based Pharmacokinetic Model for Pregnant Women to Predict the Pharmacokinetics of Drugs Metabolized Via Several Enzymatic Pathways. Clinical pharmacokinetics. 2018 Jun; [PubMed PMID: 28924743]
American Geriatrics Society 2019 Updated AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults. Journal of the American Geriatrics Society. 2019 Jan 29; [PubMed PMID: 30693946]
McClure FL,Niles JK,Kaufman HW,Gudin J, Concurrent Use of Opioids and Benzodiazepines: Evaluation of Prescription Drug Monitoring by a United States Laboratory. Journal of addiction medicine. 2017 Nov/Dec [PubMed PMID: 28953504]
Ku LC,Hornik CP,Beechinor RJ,Chamberlain JM,Guptill JT,Harper B,Capparelli EV,Martz K,Anand R,Cohen-Wolkowiez M,Gonzalez D, Population Pharmacokinetics and Exploratory Exposure-Response Relationships of Diazepam in Children Treated for Status Epilepticus. CPT: pharmacometrics [PubMed PMID: 30267478]
Zaccara G,Giannasi G,Oggioni R,Rosati E,Tramacere L,Palumbo P,convulsive status epilepticus study group of the uslcentro Toscana, Italy., Challenges in the treatment of convulsive status epilepticus. Seizure. 2017 Apr [PubMed PMID: 28282553]
Mekonnen AB,McLachlan AJ,Brien JA, Effectiveness of pharmacist-led medication reconciliation programmes on clinical outcomes at hospital transitions: a systematic review and meta-analysis. BMJ open. 2016 Feb 23 [PubMed PMID: 26908524]
Taran Z,Namadian M,Faghihzadeh S,Naghibi T, The Effect of Sedation Protocol Using Richmond Agitation-Sedation Scale (RASS) on Some Clinical Outcomes of Mechanically Ventilated Patients in Intensive Care Units: a Randomized Clinical Trial. Journal of caring sciences. 2019 Dec [PubMed PMID: 31915621]
Manders L,Abd-Elsayed A, Mandatory Review of Prescription Drug Monitoring Program Before Issuance of a Controlled Substance Results in Overall Reduction of Prescriptions Including Opioids and Benzodiazepines. Pain physician. 2020 Jun [PubMed PMID: 32517396]